Table 5 Results of multivariate analysis for PFW and OS of 144 patients

From: BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome

 

Hazard ratio

95% CI

P -value

Progression-free survival

 BRAF (mutant vs wt)

2.8

(1.4–5.7)

0.004

 Tumor grade (3 vs 1–2)

2.0

(1.3–3.2)

0.001

 Metastasectomy (yes vs no)

0.5

(0.3–0.8)

0.004

Overall survival

 BRAF (mutant vs wt)

5.3

(2.5–11.3)

<0.001

 Tumor grade (3 vs 1–2)

2.6

(1.6–4.4)

<0.001

 Metastasectomy (yes vs no)

0.6

(0.3–0.9)

0.02

 Number of treatment lines (first vs ⩾second line)

0.4

(0.2–0.7)

0.009

  1. Abbreviation: CI=Confidence interval.
Back to article page